Valneva (VALN) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Do insiders & institutionals hold more shares of RXRX or VALN?

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media prefer RXRX or VALN?

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Valneva. MarketBeat recorded 6 mentions for Recursion Pharmaceuticals and 5 mentions for Valneva. Valneva's average media sentiment score of 0.78 beat Recursion Pharmaceuticals' score of 0.72 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RXRX or VALN more profitable?

Valneva has a net margin of -43.08% compared to Recursion Pharmaceuticals' net margin of -961.32%. Valneva's return on equity of -43.05% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-961.32%	-74.70%	-54.02%
Valneva	-43.08%	-43.05%	-16.23%

Do analysts recommend RXRX or VALN?

Recursion Pharmaceuticals currently has a consensus target price of $7.00, suggesting a potential upside of 31.46%. Valneva has a consensus target price of $15.50, suggesting a potential upside of 139.38%. Given Valneva's stronger consensus rating and higher possible upside, analysts plainly believe Valneva is more favorable than Recursion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Valneva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, RXRX or VALN?

Recursion Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500.

Which has stronger earnings & valuation, RXRX or VALN?

Valneva has higher revenue and earnings than Recursion Pharmaceuticals. Valneva is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$58.84M	36.79	-$463.66M	-$1.77	-3.01
Valneva	$183.52M	3.00	-$13.25M	-$1.19	-5.44

Summary

Valneva beats Recursion Pharmaceuticals on 11 of the 15 factors compared between the two stocks.